Imugene MD & CEO, Ms Leslie Chong said, “We are excited to commence this importantPhase 2 trial with PD1-Vaxx after being approached by the leading colorectal canceroncologists from both Australia and the UK. The study costs are partially funded beingInvestigator Sponsored studies, and fall within current cash flow forecasts, she added
They approached us and we are not up for all the costs.
IMHO this is important as it looks like the word is getting around about IMU.
Ann: New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS, page-26
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.002(4.65%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $732.0K | 16.76M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1799587 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 1003772 | 13 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |